이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RemeGen 관리

관리 기준 확인 3/4

RemeGen's CEO는 Jianmin Fang, Oct2008 에 임명되었습니다 의 임기는 15.67 년입니다. 총 연간 보상은 CN¥ 14.66M, 37% 로 구성됩니다. 37% 급여 및 63% 보너스(회사 주식 및 옵션 포함). 는 HK$ 2.62B 가치에 해당하는 회사 주식의 11.44% 직접 소유합니다. 2.62B. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 4.1 년입니다.

주요 정보

Jianmin Fang

최고 경영자

CN¥14.7m

총 보상

CEO 급여 비율	37.0%
CEO 임기	15.7yrs
CEO 소유권	11.4%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jianmin Fang 의 보수는 RemeGen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥15m	CN¥5m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥27m	CN¥5m	-CN¥999m
Sep 30 2022	n/a	n/a	CN¥276m
Jun 30 2022	n/a	n/a	CN¥231m
Mar 31 2022	n/a	n/a	CN¥174m
Dec 31 2021	CN¥8m	CN¥4m	CN¥276m

보상 대 시장: Jianmin 의 총 보상 ($USD 2.02M )은 Hong Kong 시장( $USD 452.40K ).

보상과 수익: Jianmin 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jianmin Fang (61 yo)

15.7yrs

테뉴어

CN¥14,658,000

보상

Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. He has been Director, Chief Executive Officer and served as Chief Scientific Officer of RemeGen Co. Ltd. since October 16, 2008 to 2023 and redesignated a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jianmin Fang	Co-Founder	15.7yrs	CN¥14.66m	11.44% CN¥ 2.5b
Ruyi He	Chief Medical Officer	no data	CN¥24.01m	0.074% CN¥ 16.6m
Jian Lin	Executive Director	no data	CN¥1.13m	데이터 없음
Shaojing Tong	CFO & Joint Company Secretary	less than a year	데이터 없음	데이터 없음
Kaisheng Huang	Chief Operating Officer	no data	데이터 없음	데이터 없음
Marie Zhu	Chief Technical Officer	no data	데이터 없음	데이터 없음
Zhulun Wang	Chief Scientific Officer	no data	데이터 없음	데이터 없음
Daniel Ross	Chief Business Officer	less than a year	데이터 없음	데이터 없음
Xiaoming Yang	Chief Manufacturing Officer	no data	데이터 없음	데이터 없음
Pak Yu Tam	Joint Company Secretary	4.1yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: 9995 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jianmin Fang	Co-Founder	15.7yrs	CN¥14.66m	11.44% CN¥ 2.5b
Ruyi He	Chief Medical Officer	4.1yrs	CN¥24.01m	0.074% CN¥ 16.6m
Jian Lin	Executive Director	15.9yrs	CN¥1.13m	데이터 없음
Lorne Alan Babiuk	Member of Scientific Advisory Board	no data	CN¥125.00k	데이터 없음
Gang Pei	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Weidong Wang	Co-Founder & Executive Chairman	10.7yrs	CN¥15.15m	데이터 없음
Liqiang Wang	Non-Executive Director	4.1yrs	데이터 없음	4.69% CN¥ 1.0b
Xiaodi Su	Non-Executive Director	4.1yrs	데이터 없음	데이터 없음
Xianjing Hao	Independent Non-Executive Director	4.1yrs	CN¥300.00k	데이터 없음
Guangke Ren	Chairman of the Supervisory Committee	4.1yrs	데이터 없음	데이터 없음
Lan Ma	Independent Non-Executive Director	3yrs	CN¥300.00k	데이터 없음
Yunjin Chen	Independent Non-Executive Director	2.1yrs	CN¥300.00k	데이터 없음

4.1yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 9995 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

RemeGen 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Less than half of directors are independent

RemeGen Co., Ltd., Annual General Meeting, Jun 29, 2022

Recent updates

RemeGen Co., Ltd. Announces Phase III Clinical Study of Disitamab Vedotin for Injection for the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis Met Primary Study Endpoint

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

Full year 2023 earnings released: CN¥2.80 loss per share (vs CN¥1.88 loss in FY 2022)

New minor risk - Profitability

RemeGen Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer At ESGO 2024

Full year 2023 earnings released: CN¥2.86 loss per share (vs CN¥1.88 loss in FY 2022)

RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023

New minor risk - Share price stability

RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA

RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology

Third quarter 2023 earnings released

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Second quarter 2023 earnings released: CN¥0.70 loss per share (vs CN¥0.38 loss in 2Q 2022)

RemeGen Co., Ltd. Announces Results of Phase III Study on Telitacicept for Treatment of Rheumatoid Arthritis in China

New minor risk - Share price stability

RemeGen Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

Remegen Co., Ltd. Receives Ethics Approval for the Phase I Clinical Trial in Australia

Now 21% undervalued after recent price drop

Full year 2022 earnings released: CN¥1.81 loss per share (vs CN¥0.57 profit in FY 2021)

RemeGen Co., Ltd. Announces FDA Approves Ind Application for Telitacicept for Treatment of gMG and Grants It Fast Track Designation

National Medical Products Administration Approves IND Application for RemeGen’s Disitamab Vedotin for Injection, Given Intravenously, in Combination with Gemcitabine Hydrochloride for Injection, Given Intravesically, for Treatment of NMIBC

RemeGen Co., Ltd.'s RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

Less than half of directors are independent

RemeGen Co., Ltd. Announces Telitacicept Propose to Grant Telitacicept Breakthrough Therapy Designation for the Treatment of Generalised Myasthenia Gravis

RemeGen Co., Ltd. Announces Results of Phase Ii Clinical Study of Telitacicept for Treatment of Myasthenia Gravis (MG) in China

Third quarter 2022 earnings released: CN¥0.37 loss per share (vs CN¥0.74 profit in 3Q 2021)

RemeGen Co., Ltd. to Report Nine Months, 2022 Results on Oct 27, 2022

Remegen Co., Ltd. Receives Orphan Drug Designation from FDA for Treatment of Myasthenia Gravis

Investor sentiment deteriorated over the past week

RemeGen Co., Ltd. Announces Preliminary Result of Telitacicept in the Phase III Comfirmatory Study to Treat Systemic Lupus Erythematosus in China

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released

RemeGen Co., Ltd. to Report Q2, 2022 Results on Aug 26, 2022

RemeGen Co., Ltd., Annual General Meeting, Jun 29, 2022

RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director

Less than half of directors are independent

RemeGen Co., Ltd. Announces Executive Changes

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Forecast breakeven date moved forward to 2022

Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

RemeGen Co., Ltd. Completes the Phase II Clinical Study for Telitacicept to Treat Patients with Primary Sjögren's Syndrome (pSS) in China and Obtained the Relevant Data Readout

RemeGen Co., Ltd. Announces National Medical Products Administration (Nmpa) Grants Conditional Marketing Approval for Disitamab Vedotin for the Treatment of HER2 Expressing Locally Advanced or Metastatic Urothelial Carcinoma

Forecast breakeven date pushed back to 2023

Forecast breakeven date moved forward to 2021

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment

Forecast to breakeven in 2023

No longer forecast to breakeven

Remegen Co., Ltd. Announces That the National Medical Products Administration (Nmpa) Has Accepted the New Drug Application

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령